Develops antibody therapies for infectious diseases and cancer, focusing on leveraging transgenic cattle technology.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company based in Sioux Falls, South Dakota, specializing in the development of immunotherapies centered on human antibodies. Using advanced genetic engineering and antibody science, SAB has pioneered the creation of transchromosomic bovine herds capable of producing fully human antibodies. These antibodies target a spectrum of diseases, ranging from infectious diseases like COVID-19 and influenza, to immune and autoimmune disorders such as type 1 diabetes, organ transplantation, and cancer.
Central to SAB's innovative approach is its proprietary DiversitAb immunotherapy platform, which enables the production of fully-human polyclonal antibodies without relying on human donors. This platform underpins SAB's lead product candidates, including SAB-185 and SAB-176. SAB-185, currently in Phase III clinical trials, represents a fully-human polyclonal antibody therapeutic aimed at combating COVID-19. Meanwhile, SAB-176 is being developed to treat or prevent severe cases of influenza. In addition to these advanced-stage candidates, SAB is advancing pre-clinical product candidates such as SAB-142, targeting autoimmune diseases like type 1 diabetes and conditions related to organ transplant induction/rejection.
Founded in 2014, SAB Biotherapeutics continues to drive innovation in biopharmaceuticals, leveraging its expertise in antibody technology to address significant medical challenges. Collaborating with healthcare partners and researchers, SAB remains committed to advancing therapeutic solutions that can potentially transform treatment outcomes for patients worldwide.